Posts in the “EGFR EGFR” category:

Lung Cancer Alliance praises NCI’s new ALCHEMIST trial

Posted by Samantha Powell on August 19th, 2014 |

Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute’s (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed. “This trial demonstrates the power of CT screening to open […]

NCI Launches Molecular Medicine Clinical Trials; Response Genetics Nabs Profiling Contract

Posted by Samantha Powell on August 18th, 2014 |

The National Cancer Institute said today it has launched new clinical trials that will use tumor sequencing and genetic markers to help determine whether therapies targeting genetic alterations can prevent lung cancer recurrence. Separately, Response Genetics said it has been awarded a “multi-million dollar” subcontract from Leidos Biomedical Research, a contractor for the NCI-sponsored Frederick […]

GEOFFREY OXNARD: How Do I Treat Patients with Lung Cancer Harboring EGFR T790M?

Posted by Samantha Powell on July 5th, 2014 |

T790M is a point mutation in the EGFR gene that is associated with resistance to epidermal growth factor receptor (EGFR) kinase inhibitors like erlotinib and gefitinib. Some of the most exciting results presented at this year’s American Society of Clinical Oncology Annual Meeting have to do with new inhibitors targeting the EGFR T790M mutation. Given […]

New Data for Gilotrif Shows a Significant Improvement in Overall Survival in Lung Cancer Patients Whose Tumors Have the Most Common EGFR Mutation

Posted by Samantha Powell on May 20th, 2014 |

Date: 5/20/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/277021.php Boehringer Ingelheim has announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common epidermal growth factor receptor (EGFR) mutation (exon 19 deletion) lived […]

Boehringer Ingelheim’s Lung Cancer Drug Ups OS in Patients With EGFR Mutations

Posted by Samantha Powell on May 15th, 2014 |

Date: 5/15/14 Outlet Full Name: Drug Discovery and Development Author: No author http://www.dddmag.com/news/2014/05/boehringer-ingelheim%E2%80%99s-lung-cancer-drug-ups-os-patients-egfr-mutations Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase 3 trials (LUX-Lung 3 and LUX-Lung 6). The analysis showed patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations […]

Lung Cancer Patient Awaits Test Results

Posted by Samantha Powell on May 9th, 2014 |

News Headline: Lung Cancer Patient Awaits Test Results Date: 5/9/14 Outlet Full Name: NBC Bay Area Author: Liza Meak, David Burgess http://www.nbcbayarea.com/news/health/Lung-Cancer-Patient-Awaits-Test-Results-258694071.html Nearly five months after her lung cancer diagnosis, 39-year-old Molly Golbon is used to getting poked, prodded and scanned. But waiting for the results doesn’t get any easier. As difficult as it is, […]

Comparison of Treatments for Advanced Lung Cancer Shows Chemotherapy May Be Best For Certain Patients

Posted by Samantha Powell on April 9th, 2014 |

Date: 4/9/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/275193.php Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with […]

Immunotherapy Data Heralds New Era of Lung Cancer Treatment

Posted by Samantha Powell on March 26th, 2014 |

Date: 3/26/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/274533.php A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy – treatments that […]